The impairment of cell viability in tumor lines with intermediate levels of HER1 and HER2, as well as lines with resistance driving mutations suggest a set of patients that could benefit from this therapeutic approach, for which the clinical benefit of approved MAbs has been limited. This evidence concerns the gene EGFR and neoplasm.